Differential regulation of vascular angiotensin I-converting enzyme in hypertension.

Fernández-Alfonso, Marisol; Kreutz, Reinhold; Zeh, Karin; Liu, Yixian; Ganten, Detlev; Paul, Martin

doi:10.1161/01.hyp.24.3.280

Cited by 23 publications

(19 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, plasma ACE activity did not significantly differ among WKY rats, SHR-SP, and sodium-loaded SHR-SP. These results support previous findings (10,11). Therefore, blood pressure might have more influence in vascular than in plasma ACE-dependent angiotensin II formation (11).…”

Section: Discussionsupporting

confidence: 92%

“…We previously reported that ACE activity is significantly higher in the aortae of SHR-SP than WKY rats, and even more so in those of sodium-loaded SHR-SP than in SHR-SP (21). In genetically hypertensive models, such as SHR and SHR-SP, ACE expression in the vasculature is upregulated and angiotensin II action against blood vessels is strengthened (10,22). The present study found that telmisartan, but not valsartan, reduced ACE activity via its PPARγ agonistic effect, and this might result in a decrease of angiotensin II action including NAD(P)H oxidase in the vascular tissues.…”

Section: Fig 5 Ace Activities In Wky Rats Placebo (P)- Telmisartamentioning

confidence: 99%

See 1 more Smart Citation

Inhibition of Vascular Angiotensin-Converting Enzyme by Telmisartan via the Peroxisome Proliferator-Activated Receptor .GAMMA. Agonistic Property in Rats

Jin

Kimura

Kirimura³

et al. 2007

Hypertens Res

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Section: Fig 5 Ace Activities In Wky Rats Placebo (P)- Telmisartamentioning

confidence: 99%

Inhibition of Vascular Angiotensin-Converting Enzyme by Telmisartan via the Peroxisome Proliferator-Activated Receptor .GAMMA. Agonistic Property in Rats

Jin

Kimura

Kirimura³

et al. 2007

Hypertens Res

View full text Add to dashboard Cite

“…By replacing drinking water with a 1% NaCl solution, these animals show accelerated organ damage such as stroke, cerebral edema, renal dysfunction, and cardiac hypertrophy (19,20). Sodium loading enhances the activity of angiotensin-converting enzyme (ACE) in the brain and aorta in these animals, which in turn, can exaggerate organ damage (21,22).…”

Section: Discussionmentioning

confidence: 99%

Chronopharmacology of Angiotensin II–receptor Blockers in Stroke-Prone Spontaneously Hypertensive Rats

et al. 2011

View full text Add to dashboard Cite

Abstract. Protective effect of valsartan (Val), an angiotensin II (AII)-receptor blocker (ARB), against organ damage is reported to depend on the dosing time in hypertensive patients. Dosingtime-dependent effect of Val on survival of stroke-prone spontaneously hypertensive rats (SHRSP) under a 12-h lighting cycle was examined. Val (4 mg/kg per day) and olmesartan medoxomil (OM) (1 mg/kg per day), another ARB with a slower dissociation from the AII receptor, were given once daily at 2, 8, 14, or 20 HALO (hours after lights on). Dosing-time-dependent differences in plasma drug concentrations and effect on blood pressure (BP) were also evaluated. Survival of SHRSP showed a dosing-time-dependent change during Val therapy, with a peak at 2 HALO and a trough at 14 HALO. OM equally prolonged survival in all groups. The BP-lowering effect persisted for more than 24 h after dosing of Val at 2 HALO and of OM at 2 and 14 HALO, but disappeared at 5.5-h after Val dosing at 14 HALO. Plasma concentrations of Val and OM were higher after dosing at 2 HALO than at 14 HALO. These results suggest that the chronopharmacological phenomenon of Val was partly due to the dosing-time-dependent difference in plasma concentration and subsequent duration of the antihypertensive effect. Slower dissociation of OM from AII receptors might have blunted a potential dosing-time-dependent event.

show abstract

“…By replacing drinking water with a 1% NaCl solution, organ damage such as stroke, cerebral edema, renal dysfunction, and cardiac hypertrophy are accelerated (Inada et al, 1995;Blezer et al, 1998). Sodium loading enhances the activity of ACE in the brain and aorta in these animals (Mizuno et al, 1981;Fernandes-Alfonso et al, 1994), which in turn can exaggerate organ damage (Bader, 2002;Hanes et al, 2004). Although many chronopharmacological profiles have been reported for antihypertensive agents, information concerning the dosing time-dependent prevention of organ damage is limited, and no information is available concerning the dosing time-dependent effect on survival rate.…”

Section: Discussionmentioning

confidence: 99%

Dosing Time-Dependent Effect of Temocapril on the Mortality of Stroke-Prone Spontaneously Hypertensive Rats

Nozawa

Sugimoto²,

Ohmori³

et al. 2005

J Pharmacol Exp Ther

View full text Add to dashboard Cite

This study was undertaken to evaluate a dosing time-dependent effect of temocapril, an angiotensin-converting enzyme (ACE) inhibitor, on the mortality of stroke-prone spontaneously hypertensive rats (SHRSP). Temocapril (1 mg/kg/day) prolonged the survival rate of these animals, with a maximum effect after dosing at the early resting period and a minimum effect after dosing at the early active period. The pharmacokinetics of temocaprilat, an active metabolite of temocapril, did not differ significantly between the two dosing times. However, the inhibition of ACE activity in serum and organs (brain and aorta) and the reduction of blood pressure were significantly greater after dosing at the early resting period than at the early active period. These data suggest that the effect of temocapril on the mortality of SHRSP depends on the time of dosing, with a maximum effect seen after dosing at the early resting period. Dosing time-dependent differences in the pharmacodynamics of temocapril might be involved in explaining this phenomenon.Angiotensin-converting enzyme (ACE) inhibitors are widely used in the treatment of hypertension and related diseases. These agents have been shown to improve the morbidity and mortality of patients with hypertension (Kostis, 1995;Hansson et al., 1999) and are recommended as a firstline drug for the treatment of hypertension (European Society of Hypertension-European Society of Cardiology Guidelines Committee, 2003).There is increasing evidence that the effectiveness and/or toxicity of many agents are affected by their time of dosing (Cui et al., 2004;Filipski et al., 2004;Matsunaga et al., 2004;Tsuruoka et al., 2004). A chronopharmacological approach seems to be desirable for developing a more effective and safe dosage regimen. There are precedents for this approach in clinical practice (Tsuruoka et al., 2003;Debon et al., 2004;Shimonov et al., 2005).Previous animal (Oosting et al., 1999) and human (Palatini et al., 1992;Witte et al., 1993;Sunaga et al., 1995) studies have shown dosing time-dependent differences in the blood pressure-lowering effects of ACE inhibitors. In addition, the preventive effect of an ACE inhibitor for cardiac hypertrophy in hypertensive animals was reported to depend on its dosing time (Sugimoto et al., 2001). However, it remained to be determined whether the morbidity and mortality of patients with hypertension are affected by the dosing time of ACE inhibitors. The present study aimed to address this issue using stroke-prone spontaneously hypertensive rats (SHRSP), an animal model of human stroke (Okamoto et al., 1974;Yamori et al., 1976). Temocapril is a nonsulfhydryl ACE inhibitor, and its active metabolite (temocaprilat) is eliminated by the renal and biliary routes (Suzuki et al., 1993). Renal function decreases with age; however, our recent observation that the plasma accumulation of temocaprilat is low during repeated treatments in the elderly indicates that temocapril is a safe antihypertensive drug for these patients (Arakawa et al., 2005). Te...

show abstract

Differential regulation of vascular angiotensin I-converting enzyme in hypertension.

Cited by 23 publications

References 35 publications

Inhibition of Vascular Angiotensin-Converting Enzyme by Telmisartan via the Peroxisome Proliferator-Activated Receptor .GAMMA. Agonistic Property in Rats

Inhibition of Vascular Angiotensin-Converting Enzyme by Telmisartan via the Peroxisome Proliferator-Activated Receptor .GAMMA. Agonistic Property in Rats

Chronopharmacology of Angiotensin II–receptor Blockers in Stroke-Prone Spontaneously Hypertensive Rats

Dosing Time-Dependent Effect of Temocapril on the Mortality of Stroke-Prone Spontaneously Hypertensive Rats

Contact Info

Product

Resources

About